Gilead Phase III trial of remdesivir for COVID-19 shows 65 percent are 'more likely' to improve by day 11
Gilead Sciences said on Monday that remdesivir, the experimental drug being tested for COVID-19, showed that 65 percent of moderately ill patients had improvement after 11 days.
via FOX NEWS https://ift.tt/2MmAjbm
Hello! my name is Naveed, and have much interest to read and share news with my family and friends. 
0 Comments